Nasus Pharma is trading 5.9% down at $3.77 amid a broadly weaker market.
- The Nasdaq Composite is down 0.68%, with risk assets pressured by elevated Treasury yields, tariff concerns, and geopolitical headlines.
- No fresh company-specific negative announcement was identified on August 24, 2026.
- Recent coverage highlighted the SEC effectiveness notice enabling potential registered financing activity; first-half results showed increased cash but continuing losses.